Purified proteins Recombinant proteins Whole inactivated or attenuated organisms DNA encoded antigens Bacterial products Toxins Cytokines, peptides Oil.

Slides:

Advertisements

Similar presentations

Response in infants Polyclonal activation B Cell types B cell responses to antigens In xid mice (BTK-) Antigen types B Cell Antigen Receptor TI-2TI-1 Mature.

Advertisements

Potential prophylactic BCG Prime-booster Gaëlle Noël Kidist Bobosha Subgroup A2 March 16 th, 2011.

Applications of Nanoparticles for Delivery of Therapeutic Agents Frank Jeyson Hernández Topics of Nanobiotechnology 30 June, 2004.

Vaccines Robert Beatty MCB150. Passive vs Active Immunity  Passive immunization transfer of antibodies  Vaccines are active immunizations (mimic natural.

Antigens Where we’re going- Immunogenicity vs antigenicity

Acknowledgements Dept of Chemical Engineering, Monash Materials and Methods The core nanoparticles will be composed of mesoporous silica with the target.

How Cells of the Immune System “See” and Respond to Antigen

BIOT 307 Kuby, Ch. 3, Antigens March, General Introduction Specificity due to recognition of antigenic determinants or epitopes Epitopes = immunologically.

Active and passive immunization Immunity to infectious microorganisms: Immunity to infectious microorganisms: 1- Active immunization *** natural processes.

Display of the Viral Epitopes on Lactococcus lactis: A Model for Food Grade Vaccine against EV71.

Making Vaccines.

General classes of vaccines An induced mobilization of the immune response for the purpose of therapeutic benefit. Preventative: infectious agents Therapeutic:

Immunoprevention. Definition By using immunological agents to construct, improve or inhibit immune response, people can prevent some diseases.

Adapted from: Project Lead The Way Making Vaccines powerpoint

Acquired Immunity. Acquired Immunity is more specialized than other mechanisms of immunity. Acquired Immunity may be a cell-mediated or it may be a humoral.

Viral Vaccine Types Viruses are inactivated with chemicals such as formaldehyde. Inactivated (killed) vaccines cannot cause an infection, but they.

Adaptive/Acquired Immunity

Effects of Vaccines Thomas D. Overbay, DVM Expedite.

Name of presentation Month 2009 Using layered double hydroxide nanoparticles conjugated with CpG to polarise immune responses from Th2 to Th1 bias Shiyu.

Vaccines: A Molecular View

Vaccines H.Sidra Yasin (BIOT 412). Learning objectives What are the Methods to produce the vaccines How we can modify the Vaccines What are the Routs.

14. Immunodiagnosis, Immunotherapy & Vaccination 王家鑫， MD College of Veterinary Medicine.

Modular Nanodevices for Creation of Smart Adaptable Vaccine Delivery Vehicles Tarek M. Fahmy Dept. of Biomedical Engineering, Yale University Several key.

Innate Immune Response innate soluble mediators & receptors ( innate soluble mediators & receptors ) Lecture 3 8/9/2015.

Biotechnology Vaccines Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:

Drug Carrier Systems Targeted to Widely Dispersed Cells Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College.

Making Vaccines. Effective Vaccines Have low levels of side effects or toxicity. Protect against exposure to natural, or wild forms of the pathogen. Should.

Drug Carrier Systems Targeted to Widely Dispersed Cells Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College.

B Cell Activation and Antibody Production Chapter 12.

What is phage display? An in vitro selection technique using a peptide or protein genetically fused to the coat protein of a bacteriophage.

Vaccines Dr. Sarah I. Bukhari 324 PHT PhD in Clinical Microbiology

Vaccine Introduction Fahareen-Binta-Mosharraf MNS.

GOLD NANOPARTICLES: A POSSIBLE CURE FOR PANCREATIC CANCER

Adjuvants: Introduction

*1A.Majid Eslahtalab, 2Ali Badiee

Lecture Outline Antigens Definition Exogenous Endogenous

Lecture 16 Cellular Cooperation and Antigen Recognition

Adjuvants Chemical substance that can be added to a vaccine in order to enhance the immune response to the vaccine.

Moral Monday BW Should patients be given refunds when a vaccine doesn’t work?

Pattern recognition receptors (PRRs)

Some general features of immune responses. A

Chapter 43 The Immune System.

Manipulation of the Immune Response Vaccination

Biological (Organic) Molecules

Avoiding Immune Detection

Making Vaccines.

Foreign agenses, molecules, cells

Novel vaccine adjuvants for infectious diseases aninal

Vaccines Vaccines are given to prevent, or minimize the severity of, disease Vaccination elicits an immune response which has “memory”

Advances in Specific Immunotherapy for Prostate Cancer

Immune System Review.

Adjuvants: Immunostimulatory

Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity by Mikael Maksimow, Mari.

Housekeeping May 1st 31 field trip, transport yourself to the Shady Lakes, pm. PCR results gel is posted (report) This lecture paper discussion.

Figure 2 Invariant natural killer T (iNKT) cells promote atherogenesis

Volume 36, Issue 5, Pages (May 2012)

Immunization/Vaccination

Volume 27, Issue 2, Pages (August 2007)

Innovations in formulation and delivery systems for TLR7/8 agonists.

Presented by Whitney Souery 11/28/2018

By JERLIN G. Research Scholar, Department of Physics.

Volume 27, Issue 4, Pages (October 2007)

Volume 4, Issue 4, Pages (April 1996)

Volume 19, Issue 3, Pages (September 2003)

Notch 1 Signaling Regulates Peripheral T Cell Activation

A Comprehensive Platform for Ex Vivo T-cell Expansion Based on Biodegradable Polymeric Artificial Antigen-presenting Cells Erin R Steenblock, Tarek M.

CD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4

CD14: Chaperone or Matchmaker?

Volume 25, Issue 4, Pages (April 2017)

Presentation transcript:

Purified proteins Recombinant proteins Whole inactivated or attenuated organisms DNA encoded antigens Bacterial products Toxins Cytokines, peptides Oil in water emulsions Aluminum compounds Mineral salts Polymers Antigens Immune Potentiators Delivery Carriers Modern Vaccine Components

MOTIVATION A Modular approach to constructing vaccines Adaptor Biodegradable polymer Recognition elements Antigen Protective transport elements Endosomal Disruption element S S Protection during transport Dendritic Cell recognition Encapsulated antigen subunit Encapsulated Endosomal disruptor Transepithelial cell transport nm

Biodegradable polymer nanoparticles Encapsulated antigen subunit nm A Sustained release of encapsulated antigen from a biodegradable core. 50/50 Poly (lactide-co- glycolide) polymer

Adaptor Proteins nm B High density surface presentation of adaptor elements

Adaptor Proteins Surface presentation is long-lived with sustained release of antigen Biotin-PE C Long-lived surface presentation

nm Polysaccharide Backbone TLR4 Ligand Lipid A Anchor + Antigen-loaded Biodegradable Nanoparticle Antigen-Delivery to Dendritic Cells: Targeting Toll Like Receptor (TL4)

nm Polysaccharide Backbone TLR4 Ligand Lipid A Anchor + Antigen-loaded Biodegradable Nanoparticle Antigen-Delivery to Dendritic Cells: Targeting Toll Like Receptor (TL4) LPS/OVA Uncoated/OVA Blank Inject SubQ Isolate Splenocytes Stimulate on an OVA coated Plate 7 days OR Oral Feeding

nm Polysaccharide Backbone TLR4 Ligand Lipid A Anchor + Antigen-loaded Biodegradable Nanoparticle Antigen-Delivery to Dendritic Cells: (Subcutaneous Route) Targeting Toll Like Receptor (TL4) Stimulation of Splenocytes from vaccinated mice with OVA antigen OVA (ug/ml) Blank Particles Unmodified Particles/OVA LPS Particles/OVA Proliferation Index (Post 3 Days)

nm Polysaccharide Backbone TLR4 Ligand Lipid A Anchor + Antigen-loaded Biodegradable Nanoparticle Antigen-Delivery to Dendritic Cells: (Oral Route) Targeting Toll Like Receptor (TL4) Oral Vaccination followed by OVA antigen Stimulation of Splenocytes OVA (ug/ml) Blank Particles Unmodified Particles/OVA LPS Particles/OVA Proliferation Index (Post 3 Days)

pH < 5 37 C Elastin (Expanded State) Elastin-Coated nanoparticle nm pH > 5 37 C pH = 7pH = Time (hrs) Drug released (mg) Elastin (pH=2) No Elastin (pH= 2) Surface modification Protection during Transport: Surface modification with pH responsive polypeptides:

PATHFORWARD Optimal Assembly of modular units Transport Recognition of DC subsets Antigen presentation Ira Mellman Mark Saltzman Michael Caplan Robert Samstein Gilbert Addo Stacey Demento Erin Steenblock Thanks to:

Adaptor Biodegradable polymer Recognition elements Antigen Endosomal Disruption element Dendritic Cell recognition Encapsulated antigen subunit Encapsulated Endosomal disruptor Transepithelial cell transport nm D Mediating transport and recognition